Fatty Liver and Pancreatic Steatosis

Launched by MARIA MARTA PISKORZ · Jan 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the connection between fatty liver disease and pancreatic health. Specifically, researchers want to find out how common it is for patients with fatty liver to also have a condition called pancreatic steatosis, where fat builds up in the pancreas. They also aim to see how many of these patients have exocrine pancreatic insufficiency (EPI), which means the pancreas doesn't produce enough enzymes to help with digestion.

To participate in this study, you need to be over 18 years old and have been diagnosed with a specific type of fatty liver disease known as Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). The trial is not yet recruiting participants, but once it starts, those eligible will undergo tests like a fecal elastase measurement and an endoscopic ultrasound (EUS) to check the health of their pancreas. It's important to note that certain conditions, such as significant alcohol use or specific liver diseases, will exclude individuals from participating. Overall, this study aims to shed light on how fatty liver impacts pancreatic function, which could help improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
• Exclusion Criteria:
• • - Alcohol consumption \>20 g/day in women, \>30 g/day in men
• • Chronic hepatitis B or C infection
• • Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
• • Hereditary hemochromatosis
• • Wilson's disease
• • Alpha-1 antitrypsin deficiency
• • Celiac disease
• • Uncontrolled thyroid disease
• • Active or chronic infectious disease
• • Active cancer or ongoing treatment
• • Chronic renal insufficiency
• • Pregnancy/lactation
• • Insufficient data
• • Patients who do not complete follow-up